Results of Gemaza therapy of hemophthalmia in patients with diabetic retinopathy
https://doi.org/10.14341/2072-0351-5683
Abstract
Aim.
To evaluate efficiency of Gemaza used to treat hemophthalmia of different severity and localization.
Materials and methods.
Gemaza (5000 IU) was admnistered parabulbarly to 75 patients (78 eyes) with diabetes mellitus (DM) after dilution in0.5 ml of 0.9% sodium chloride solution. Each patient received 10 daily injections during baseline hypoglycemic therapy. Control group was comprisedof 20 patients (20 eyes) with hemophthalmia, treated by traditional drug therapy (emoxipin, dicinon, ascorutin, actovegin).
Results.
Gemaza proved a highly efficient agent showing hemoresorptive and fibrinolytic activities; it improved visual acuity in 51.3% of the patientsfrom day 5 after the onset of therapy.
Conclusion.
It is recommended to administer Gemaza soon after hemorrhage, prior to the development of proliferative processes in the vitreous bodyand retina.
To evaluate efficiency of Gemaza used to treat hemophthalmia of different severity and localization.
Materials and methods.
Gemaza (5000 IU) was admnistered parabulbarly to 75 patients (78 eyes) with diabetes mellitus (DM) after dilution in0.5 ml of 0.9% sodium chloride solution. Each patient received 10 daily injections during baseline hypoglycemic therapy. Control group was comprisedof 20 patients (20 eyes) with hemophthalmia, treated by traditional drug therapy (emoxipin, dicinon, ascorutin, actovegin).
Results.
Gemaza proved a highly efficient agent showing hemoresorptive and fibrinolytic activities; it improved visual acuity in 51.3% of the patientsfrom day 5 after the onset of therapy.
Conclusion.
It is recommended to administer Gemaza soon after hemorrhage, prior to the development of proliferative processes in the vitreous bodyand retina.
References
1. Нестеров А.П., Балашова Л.М., Бибилашвили Р.Ш., Белогуров А.А. Лечение гемофтальма при диабетической ретинопатии с применением расширенной периферической транссклеральной криопексии сетчатки в сочетании с инъекционным введением рекомбинантной проурокиназы (Гемазы) // Тезисы доклада. I Международная научно-практическая конференция «Пролиферативный синдром в офтальмологии». - М., 2000. - С. 54.
2. Полунин Г.С., Макаров И.А., Ширшиков Ю.К., Анжелова Д.В. Протеолитический препарат «Гемаза» в лечении геморрагических витреоретинальных осложнений // Тезисы доклада. I Международная научно-практическая конференция «Пролиферативный синдром в офтальмологии». - М., 2000. - С. 56-58.
3. Степанов А.В., Болквадзе Е.Р., Белогуров А.А., Товарова И.И. Возможности терапии внутриглазных травматических кровоизлияний с помощью нового фибринолитика Гемаза // Вестник офтальмологии. - 2002. - № 5. - С. 25-27.
4. Makarov I.A., Varnakov S.I., Polunin G.S., Bocharov V.E., et all. Fibrinolitic effect of gemase on lysis of fibrin symptoms of the iritis after cataract extraction. 3rd International symposium on ocular pharmacology and pharmaceutics // ISOPP. - Lisbon, Portugal, 2000.
Review
For citations:
Normatova N.M. Results of Gemaza therapy of hemophthalmia in patients with diabetic retinopathy. Diabetes mellitus. 2010;13(2):97-99. (In Russ.) https://doi.org/10.14341/2072-0351-5683
Views:
7621
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
